Ligand Pharmaceuticals Inc. (LGND)

Lifshitz & Miller announces investigation on behalf of LGND investors concerning whether LGND adequately disclosed certain deferred tax assets and outstanding convertible senior unsecured notes.

If you are an LGND investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-9780 or e-mail at